Ispire Technology Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2023 (the company’s first quarter of fiscal 2024), compared with the three months ended September 30, 2022. Financial statements are unaudited. Ispire develops, markets and sells tobacco vaping products worldwide except in the PRC and Russia, and cannabis vaping hardware primarily in the United States.
Financial performance
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $42.9 million | $26.9 million | Up 59.1% |
| Gross profit / margin | $6.9 million / 16.1% | $4.8 million / 17.8% | Profit up 43.7%; margin down 1.7 percentage points |
| Operating expenses | $7.8 million | $6.0 million | Up 29.8% |
| Operating loss | $0.9 million | $1.2 million | Loss narrowed |
| Net loss | $1.4 million | $2.0 million | Loss narrowed; loss per share was $0.03 vs. $0.04 |
| Cash from operating activities | $(12.9) million | $2.2 million | Decline of $15.1 million |
- Revenue growth reflected higher cannabis vaping sales ($17.3 million vs. $8.0 million) and tobacco vaping sales ($25.5 million vs. $18.9 million). Cannabis gross margin fell to 16.5% from 21.9%, primarily due to discounts on an older model and product mix. Tobacco gross margin was 15.8%, compared with 16.1%.
- General and administrative expense rose 49.4% to $6.7 million, reflecting expansion-related payroll, public-company professional fees and $1.0 million of stock-based compensation. Sales and marketing expense fell 28.8% to $1.1 million.
- Cash and cash equivalents were $25.7 million at September 30, down from $40.3 million at June 30. Operating cash use was driven chiefly by a $14.7 million increase in accounts receivable and a $2.4 million decrease in accounts payable. Investing and financing used $0.8 million and $0.9 million, respectively.
- Current assets were $81.6 million and current liabilities $54.0 million, for working capital of $27.6 million. The company also held a $9.2 million certificate of deposit maturing February 8, 2024.
- Total liabilities were $57.4 million. The filing reports no conventional borrowings; liabilities include $50.5 million of accounts payable to related-party supplier Shenzhen Yi Jia and $4.6 million of operating lease liabilities. Related-party amounts payable are unsecured, non-interest-bearing and have no stated due date; the filing does not clarify when the large payable is expected to be settled.
Material changes, outlook and risks
- Management said cash on hand, operating cash flows and $18.3 million of net IPO proceeds are expected to support working-capital needs for the next 12 months. Additional financing could be needed if operating conditions worsen, capital spending rises or growth is accelerated; availability and terms are not assured. No specific revenue or earnings guidance was provided.
- Customer concentration is significant: one customer represented 35% of quarterly revenue and another 16%. Accounts receivable, net, increased to $39.2 million from $24.5 million at June 30; the company recorded $225,487 of bad-debt expense and wrote off $628,359 of receivables during the quarter.
- Substantially all vaping products are purchased from Shenzhen Yi Jia, which is controlled by the chairman and co-CEO. The related-party supplier exposure, reliance on China-based manufacturing and potential supply disruptions are material risks.
- Regulatory exposure is substantial. Ispire has submitted a PMTA for one U.S. tobacco vaping product; FDA review could result in rejection or restrictions. The company has stopped marketing tobacco vaping products in the U.S. because sales did not justify regulatory and marketing costs. U.S. cannabis sales are exposed to changing state rules and federal-law restrictions; all cannabis revenue in the periods shown came from the U.S.
- Disclosure controls and procedures were deemed ineffective because controls over recording assets acquired from a controlling stockholder were lacking. The company previously restated financial statements for the three and nine months ended March 31, 2023, eliminating transferred intangible assets and related amortization. A new CFO and vice president of finance were appointed, and remediation is ongoing.
- In a separate matter, the FDA had requested information in 2021 about Aspire North America’s social-media marketing and potential youth exposure. The company responded; the FDA had not taken further action as of the filing, but the company cannot rule out future enforcement.
- The company formed a wholly owned Malaysian subsidiary in September 2023 to establish Southeast Asian manufacturing operations. Subsequent to quarter-end, it granted additional employee stock options.
Important facts for investors to verify
- Whether the company can collect the growing receivables and convert reported sales into operating cash flow.
- Payment terms, settlement timing and continuity of supply associated with the $50.5 million related-party payable and Shenzhen Yi Jia relationship.
- Progress and cost of Malaysian manufacturing, and whether it reduces dependence on the related-party supplier.
- FDA status of the PMTA and any developments concerning the FDA’s marketing inquiry, alongside changes in U.S. cannabis and vaping regulations.
- Remediation of the disclosed control weakness, and the company’s filing-status checkbox, which indicates “No” to having filed all required reports during the preceding 12 months.